title: Isradipine in the treatment of mild to moderate essential hypertension.
abstract: Male patients with supine diastolic blood pressures above 95 mmHg after placebo therapy received twice daily isradipine (Dynacirc; Sandoz) 1.25, 2.5 or 5.0 mg for 12 weeks. Blood pressures were measured every 14 days. Doses of 2.5 or 5 mg isradipine twice daily significantly reduced supine and erect mean systolic, mean diastolic and mean arterial pressures. Isradipine 1.25 mg twice daily reduced supine mean diastolic and mean arterial pressures only. A dose of 5 mg twice daily was accompanied by an increase in adverse reactions. The recommended dose of isradipine is 2.5 mg twice daily.
authors.affiliation: Department of Clinical and Experimental Pharmacology, University of Natal, Durban.
authors.forename: W P
authors.initials: WP
authors.lastname: Leary
authors.forename: B
authors.initials: B
authors.lastname: Maharaj
authors.forename: K
authors.initials: K
authors.lastname: Van der Byl
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004095:Dihydropyridines / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017275:Isradipine; D008297:Male
chemical_list: D000959:Antihypertensive Agents; D004095:Dihydropyridines; D017275:Isradipine